Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives
Martina Delsignore, Gaia Cassinari, Simona Revello, Luigi Cerbone, Federica Grosso, Marcello Arsura, Chiara Porta, Alfonso Baldi · 2025
Read Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives by Martina Delsignore, Gaia Cassinari, Simona Revello, Luigi Cerbone, Federica Grosso, Marcello Arsura, Chiara Porta, Alfonso Baldi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731717.txt.
Description
Martina Delsignore and co-authors review what decides whether immune therapy works against pleural mesothelioma, in a 2025 paper. The cancer is rare and long had few options. A dual checkpoint drug pairing helped, but responses vary wildly and survival gains stay modest. Tumor subtype matters: the two growth patterns carry different gene faults and immune neighborhoods.
The review weighs tumor-side factors like mutation load and checkpoint levels, and host-side ones like immune cell mix, tissue scaffolding, and gut microbes. It then surveys add-on strategies in trials: chemotherapy, radiation, surgery, gene-silencing drugs, vessel blockers, vaccines, and virus therapies. The authors argue matching patients by layered profiles is the way forward.
Catalog record
| CREATOR | Martina Delsignore, Gaia Cassinari, Simona Revello, Luigi Cerbone, Federica Grosso, Marcello Arsura, Chiara Porta, Alfonso Baldi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 95 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |